<DOC>
	<DOC>NCT00134953</DOC>
	<brief_summary>This study is designed to investigate the efficacy and safety of rivastigmine compared with placebo in patients with mild cognitive impairment (MCI).</brief_summary>
	<brief_title>Efficacy and Safety of Rivastigmine in Patients With Mild Cognitive Impairment</brief_title>
	<detailed_description />
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<mesh_term>Neurobehavioral Manifestations</mesh_term>
	<mesh_term>Rivastigmine</mesh_term>
	<criteria>Males or females who are one year postmenopausal or without childbearing potential Between the ages of 50 and 85 years old Mild cognitive impairment confirmed by Mini Mental State Examination (MMSE) score between 23 and 27 Cooperative, able to ingest oral medication, and able to complete all aspects of the study and capable of doing so, either alone or with the aid of a responsible caregiver, according to the investigator's judgement A current diagnosis of cerebrovascular disease, any primary neurodegenerative disorder, or any other causes of neuropsychologic disturbances or secondary dementia A current diagnosis of epilepsy or depression, or any other diagnosis that may interfere with the patient's response to study medication An advanced, severe or unstable disease of any type that may interfere with efficacy evaluations Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Mild cognitive impairment</keyword>
	<keyword>Alzheimer's disease</keyword>
	<keyword>Dementia</keyword>
	<keyword>Mild Cognitive Impairment (MCI)</keyword>
</DOC>